From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain delivers expert policy, pricing, reimbursement, and regulatory guidance, alongside best-in-class commercialization strategies. We empower pharma companies, from startups to large enterprises, to build efficient access, affordability, and distribution strategies that maximize net revenue.
Learn More
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
IntegriChain has the deepest set of drug commercialization experts in the industry. No other commercialization partner provides the depth of policy, pricing, and reimbursement insights, pulse on regulatory changes and reforms, as well as best-in-class strategy development across all aspects of drug commercialization. Whether you’re launching your first drug or managing a portfolio of hundreds, IntegriChain experts help you build net revenue efficient and connected strategies for access, affordability and distribution.
IntegriChain experts help pharmaceutical and biotech companies craft and execute strategies to optimize their government pricing (GP), contracting, and gross-to-net (GTN). With deep experience in a wide range of regulatory matters, our experts provide guidance through complex matters and conduct regular analyses to ensure your business remains compliant and scalable, quality processes are in place for the future.
Contact us
Pharmaceutical manufacturers are struggling more than ever to forecast and optimize their net revenue. IntegriChain Consulting and Advisory possess a comprehensive working knowledge of all the commercial functions as well as the broader healthcare ecosystem, across all therapeutic categories and drug archetypes. This makes them uniquely qualified to address gross-to-net strategy issues, resolve accrual management headaches, and develop tailored forecasting models.
IntegriChain experts understand all the regulations across HHS, CMS, OIG, DEA, State and other regulatory bodies. We help manufacturers understand and predict what’s coming and how these impact pricing implications. We partner with prestigious legal and accounting teams to stay on top of this changing landscape, making us well-prepared to deliver the most contemporary and actionable insights possible.
This customer had three in-line therapies across Immunology, Hematology, and Infectious Disease with another five therapies in phase III clinical trials. As is the case with many specialty therapies, the level of competition was increasing, driving the need for more aggressive commercial contracting and…
Read Case Study
This customer is one of the world’s largest Pharmaceutical manufacturers with 76 in-line drugs covering more than 100 conditions across 10 therapeutic categories and another dozen drugs in phase 3 clinical trials. Their portfolio is highly diversified, with multiple drug archetypes ranging from traditional…
Our teams bring decades of experience and expertise in understanding payer markets and how payer access varies across therapeutic categories as well as pharmacy and medical benefit products. This provides the foundation to help set and put into practice archetype-specific payer strategies that help customers achieve both patient access and net-revenue goals.
IntegriChain consultants bring a cross-functional approach to commercialization, taking into account the uniqueness of therapeutic areas, drug classes, patient bases, and pricing and reimbursement scenarios. This enables us to create highly tailored strategies that meet patient access and net revenue goals.
IntegriChain has proven expertise in designing pharmacy and provider strategies across all therapeutic areas and drug classes. We help you understand how your drug’s unique positioning, patient population, pricing schedule, and patient support requirements help pharmacies and providers help their patients gain access to products.
The latest ICyte Platform Summer Release is all about data actionability. We’ve now made it easier than ever to provide better, deeper visibility into your data within our single access platform so you can proactively simplify your everyday tasks and spend less time dealing…
Read Blog Post
One of the data quality challenges that we’ve been tackling here at IntegriChain is an issue that really seems to be resonating with life sciences access teams lately: data quality concerns around patient identifiers or patient mastering. We have spent a lot of our…
55% of legitimate prescription volume falls on the floor everyday due to challenges with the patient journey. Our knowledge of copay and other financial assistance tools, including bridge therapies and trials, allows us to enhance patient access and affordability and help with patient pull through.
Today, there are a myriad of distribution models, each of them working differently and having different implications on access. IntegriChain consultants have experience across distribution models, including working with third party logistics providers, to design and negotiate optimal agreements, regardless of the drug archetype or therapeutic category.
Successful commercialization depends on accurate, timely insights around patient, provider, payer, distribution, pharmacy, and financial performance. IntegriChain consultants, powered by the data and technology of the ICyte Platform, deliver tailored data strategies, actionable analytics, and end-to-end operational support model.
The pharmaceutical landscape is undergoing a profound transformation, marked by significant regulatory shifts and the imperative for enhanced cross-functional effectiveness. This webinar will provide a comprehensive analysis of the impact of 340B regulations and the IRA on pharmaceutical revenue and pricing strategies.
View Webinar
Preparing to launch an HCP-administered treatment can be one of the most challenging opportunities for manufacturer commercial teams in their careers. In this webinar we provide an overview of the HCP-administered playbook and essential considerations for manufacturers who are preparing to launch an HCP-administered…
